nodes	percent_of_prediction	percent_of_DWPC	metapath
Sildenafil—ABCC10—Daunorubicin—hematologic cancer	0.0479	0.0737	CbGbCtD
Sildenafil—ABCC4—Tioguanine—hematologic cancer	0.0429	0.0661	CbGbCtD
Sildenafil—ABCC10—Cytarabine—hematologic cancer	0.0423	0.065	CbGbCtD
Sildenafil—ABCC5—Mercaptopurine—hematologic cancer	0.0371	0.0571	CbGbCtD
Sildenafil—ABCC10—Gemcitabine—hematologic cancer	0.0257	0.0396	CbGbCtD
Sildenafil—ABCC10—Vincristine—hematologic cancer	0.02	0.0308	CbGbCtD
Sildenafil—ABCC5—Cisplatin—hematologic cancer	0.0187	0.0288	CbGbCtD
Sildenafil—ABCC10—Etoposide—hematologic cancer	0.0184	0.0283	CbGbCtD
Sildenafil—ABCC4—Mercaptopurine—hematologic cancer	0.0178	0.0274	CbGbCtD
Sildenafil—CYP1A1—Methoxsalen—hematologic cancer	0.0126	0.0193	CbGbCtD
Sildenafil—ABCC10—Doxorubicin—hematologic cancer	0.0125	0.0193	CbGbCtD
Sildenafil—ABCC10—Methotrexate—hematologic cancer	0.0121	0.0187	CbGbCtD
Sildenafil—CYP1A1—Bortezomib—hematologic cancer	0.0119	0.0184	CbGbCtD
Sildenafil—CYP1A1—Daunorubicin—hematologic cancer	0.0114	0.0176	CbGbCtD
Sildenafil—CYP1A1—Thalidomide—hematologic cancer	0.0104	0.016	CbGbCtD
Sildenafil—CYP1A1—Dacarbazine—hematologic cancer	0.00895	0.0138	CbGbCtD
Sildenafil—CYP2E1—Thalidomide—hematologic cancer	0.00804	0.0124	CbGbCtD
Sildenafil—CYP2C9—Bexarotene—hematologic cancer	0.00785	0.0121	CbGbCtD
Sildenafil—CYP3A7—Ifosfamide—hematologic cancer	0.00733	0.0113	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.00733	0.0113	CbGbCtD
Sildenafil—CYP1A1—Dasatinib—hematologic cancer	0.00703	0.0108	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.007	0.0108	CbGbCtD
Sildenafil—CYP3A7—Imatinib—hematologic cancer	0.007	0.0108	CbGbCtD
Sildenafil—CYP2E1—Dacarbazine—hematologic cancer	0.00691	0.0106	CbGbCtD
Sildenafil—CYP3A5—Daunorubicin—hematologic cancer	0.00686	0.0106	CbGbCtD
Sildenafil—CYP2D6—Lomustine—hematologic cancer	0.00667	0.0103	CbGbCtD
Sildenafil—CYP2C9—Idarubicin—hematologic cancer	0.0065	0.01	CbGbCtD
Sildenafil—CYP3A5—Thalidomide—hematologic cancer	0.00625	0.00961	CbGbCtD
Sildenafil—CYP3A5—Teniposide—hematologic cancer	0.00596	0.00917	CbGbCtD
Sildenafil—CYP2D6—Idarubicin—hematologic cancer	0.00594	0.00915	CbGbCtD
Sildenafil—ABCC4—Methotrexate—hematologic cancer	0.00583	0.00897	CbGbCtD
Sildenafil—CYP2C19—Bortezomib—hematologic cancer	0.00578	0.0089	CbGbCtD
Sildenafil—CYP3A5—Ifosfamide—hematologic cancer	0.0055	0.00846	CbGbCtD
Sildenafil—CYP2E1—Mitoxantrone—hematologic cancer	0.00536	0.00826	CbGbCtD
Sildenafil—CYP3A5—Imatinib—hematologic cancer	0.00525	0.00809	CbGbCtD
Sildenafil—CYP2D6—Hydroxyurea—hematologic cancer	0.00505	0.00778	CbGbCtD
Sildenafil—CYP2C19—Thalidomide—hematologic cancer	0.00504	0.00776	CbGbCtD
Sildenafil—CYP2C9—Bortezomib—hematologic cancer	0.00481	0.0074	CbGbCtD
Sildenafil—CYP2C19—Teniposide—hematologic cancer	0.00481	0.0074	CbGbCtD
Sildenafil—CYP3A4—Bexarotene—hematologic cancer	0.00456	0.00702	CbGbCtD
Sildenafil—CYP2C19—Ifosfamide—hematologic cancer	0.00444	0.00683	CbGbCtD
Sildenafil—CYP2D6—Bortezomib—hematologic cancer	0.0044	0.00677	CbGbCtD
Sildenafil—CYP3A7—Irinotecan—hematologic cancer	0.00437	0.00673	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00437	0.00673	CbGbCtD
Sildenafil—CYP3A4—Lomustine—hematologic cancer	0.00424	0.00653	CbGbCtD
Sildenafil—CYP3A4—Busulfan—hematologic cancer	0.00424	0.00653	CbGbCtD
Sildenafil—CYP2C19—Imatinib—hematologic cancer	0.00424	0.00652	CbGbCtD
Sildenafil—CYP3A5—Dasatinib—hematologic cancer	0.00422	0.00649	CbGbCtD
Sildenafil—CYP2C9—Thalidomide—hematologic cancer	0.00419	0.00645	CbGbCtD
Sildenafil—CYP2C9—Teniposide—hematologic cancer	0.004	0.00615	CbGbCtD
Sildenafil—CYP3A7—Vincristine—hematologic cancer	0.00382	0.00589	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00382	0.00589	CbGbCtD
Sildenafil—CYP3A4—Thiotepa—hematologic cancer	0.00378	0.00582	CbGbCtD
Sildenafil—CYP2C9—Ifosfamide—hematologic cancer	0.00369	0.00568	CbGbCtD
Sildenafil—CYP1A1—Dexamethasone—hematologic cancer	0.0036	0.00554	CbGbCtD
Sildenafil—CYP2C9—Imatinib—hematologic cancer	0.00352	0.00542	CbGbCtD
Sildenafil—CYP2E1—Etoposide—hematologic cancer	0.00338	0.00521	CbGbCtD
Sildenafil—CYP3A5—Irinotecan—hematologic cancer	0.00328	0.00505	CbGbCtD
Sildenafil—CYP2D6—Imatinib—hematologic cancer	0.00322	0.00496	CbGbCtD
Sildenafil—CYP2C9—Nilotinib—hematologic cancer	0.0032	0.00493	CbGbCtD
Sildenafil—CYP3A4—Methoxsalen—hematologic cancer	0.00294	0.00452	CbGbCtD
Sildenafil—CYP2D6—Nilotinib—hematologic cancer	0.00293	0.00451	CbGbCtD
Sildenafil—CYP2D6—Vinorelbine—hematologic cancer	0.0029	0.00447	CbGbCtD
Sildenafil—CYP3A7—Dexamethasone—hematologic cancer	0.00288	0.00443	CbGbCtD
Sildenafil—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00288	0.00443	CbGbCtD
Sildenafil—CYP3A5—Vincristine—hematologic cancer	0.00287	0.00441	CbGbCtD
Sildenafil—CYP3A4—Bortezomib—hematologic cancer	0.0028	0.0043	CbGbCtD
Sildenafil—CYP2C19—Prednisone—hematologic cancer	0.00279	0.0043	CbGbCtD
Sildenafil—CYP2E1—Dexamethasone—hematologic cancer	0.00278	0.00428	CbGbCtD
Sildenafil—CYP3A4—Daunorubicin—hematologic cancer	0.00267	0.00412	CbGbCtD
Sildenafil—CYP3A5—Etoposide—hematologic cancer	0.00263	0.00405	CbGbCtD
Sildenafil—PDE6G—blood—hematologic cancer	0.00237	0.0631	CbGeAlD
Sildenafil—CYP3A4—Cytarabine—hematologic cancer	0.00236	0.00363	CbGbCtD
Sildenafil—CYP3A4—Teniposide—hematologic cancer	0.00232	0.00358	CbGbCtD
Sildenafil—CYP3A5—Dexamethasone—hematologic cancer	0.00216	0.00333	CbGbCtD
Sildenafil—CYP3A4—Ifosfamide—hematologic cancer	0.00214	0.0033	CbGbCtD
Sildenafil—PDE6G—lung—hematologic cancer	0.00208	0.0553	CbGeAlD
Sildenafil—CYP3A4—Imatinib—hematologic cancer	0.00205	0.00315	CbGbCtD
Sildenafil—PDE6G—testis—hematologic cancer	0.00196	0.0522	CbGeAlD
Sildenafil—CYP3A4—Ruxolitinib—hematologic cancer	0.00193	0.00297	CbGbCtD
Sildenafil—CYP3A4—Nilotinib—hematologic cancer	0.00186	0.00287	CbGbCtD
Sildenafil—CYP3A4—Vinorelbine—hematologic cancer	0.00185	0.00284	CbGbCtD
Sildenafil—CYP2C9—Cisplatin—hematologic cancer	0.00179	0.00276	CbGbCtD
Sildenafil—CYP2D6—Vinblastine—hematologic cancer	0.00179	0.00275	CbGbCtD
Sildenafil—CYP2C19—Dexamethasone—hematologic cancer	0.00174	0.00268	CbGbCtD
Sildenafil—CYP3A4—Triamcinolone—hematologic cancer	0.00169	0.0026	CbGbCtD
Sildenafil—CYP3A4—Dasatinib—hematologic cancer	0.00165	0.00253	CbGbCtD
Sildenafil—CYP3A4—Mitoxantrone—hematologic cancer	0.00163	0.0025	CbGbCtD
Sildenafil—ADORA2A—hematopoietic system—hematologic cancer	0.00155	0.0414	CbGeAlD
Sildenafil—CYP2C9—Dexamethasone—hematologic cancer	0.00145	0.00223	CbGbCtD
Sildenafil—CYP3A4—Betamethasone—hematologic cancer	0.00145	0.00223	CbGbCtD
Sildenafil—CYP3A4—Prednisolone—hematologic cancer	0.00143	0.0022	CbGbCtD
Sildenafil—PDE6G—lymph node—hematologic cancer	0.00142	0.0379	CbGeAlD
Sildenafil—PDE5A—hematopoietic system—hematologic cancer	0.00141	0.0377	CbGeAlD
Sildenafil—CYP3A4—Prednisone—hematologic cancer	0.00135	0.00208	CbGbCtD
Sildenafil—CYP2D6—Dexamethasone—hematologic cancer	0.00133	0.00204	CbGbCtD
Sildenafil—CYP3A4—Irinotecan—hematologic cancer	0.00128	0.00197	CbGbCtD
Sildenafil—ADORA2A—gonad—hematologic cancer	0.00118	0.0314	CbGeAlD
Sildenafil—CYP3A4—Vinblastine—hematologic cancer	0.00114	0.00175	CbGbCtD
Sildenafil—CYP3A4—Vincristine—hematologic cancer	0.00112	0.00172	CbGbCtD
Sildenafil—CYP2D6—Doxorubicin—hematologic cancer	0.0011	0.00169	CbGbCtD
Sildenafil—ABCC10—hematopoietic system—hematologic cancer	0.00108	0.0288	CbGeAlD
Sildenafil—PDE5A—gonad—hematologic cancer	0.00108	0.0286	CbGeAlD
Sildenafil—ADORA2A—blood—hematologic cancer	0.00103	0.0274	CbGeAlD
Sildenafil—CYP3A4—Etoposide—hematologic cancer	0.00102	0.00158	CbGbCtD
Sildenafil—PDE5A—blood—hematologic cancer	0.000937	0.025	CbGeAlD
Sildenafil—ABCC4—hematopoietic system—hematologic cancer	0.000897	0.0239	CbGeAlD
Sildenafil—ADORA2A—testis—hematologic cancer	0.000851	0.0227	CbGeAlD
Sildenafil—CYP3A4—Dexamethasone—hematologic cancer	0.000843	0.0013	CbGbCtD
Sildenafil—ABCC5—bone marrow—hematologic cancer	0.00083	0.0221	CbGeAlD
Sildenafil—ABCC10—gonad—hematologic cancer	0.000822	0.0219	CbGeAlD
Sildenafil—PDE5A—lung—hematologic cancer	0.000822	0.0219	CbGeAlD
Sildenafil—PDE5A—testis—hematologic cancer	0.000775	0.0206	CbGeAlD
Sildenafil—ABCC5—lung—hematologic cancer	0.000752	0.02	CbGeAlD
Sildenafil—CYP2C19—hematopoietic system—hematologic cancer	0.000746	0.0199	CbGeAlD
Sildenafil—ABCC10—blood—hematologic cancer	0.000716	0.0191	CbGeAlD
Sildenafil—ABCC5—testis—hematologic cancer	0.000709	0.0189	CbGeAlD
Sildenafil—CYP3A4—Doxorubicin—hematologic cancer	0.000699	0.00108	CbGbCtD
Sildenafil—ABCC10—bone marrow—hematologic cancer	0.000693	0.0185	CbGeAlD
Sildenafil—ABCC10—lung—hematologic cancer	0.000628	0.0167	CbGeAlD
Sildenafil—CYP1A1—hematopoietic system—hematologic cancer	0.000601	0.016	CbGeAlD
Sildenafil—ABCC4—blood—hematologic cancer	0.000594	0.0158	CbGeAlD
Sildenafil—ABCC10—testis—hematologic cancer	0.000593	0.0158	CbGeAlD
Sildenafil—CYP3A5—hematopoietic system—hematologic cancer	0.000588	0.0156	CbGeAlD
Sildenafil—CYP2C9—hematopoietic system—hematologic cancer	0.000578	0.0154	CbGeAlD
Sildenafil—ABCC4—bone marrow—hematologic cancer	0.000575	0.0153	CbGeAlD
Sildenafil—PDE5A—lymph node—hematologic cancer	0.000562	0.015	CbGeAlD
Sildenafil—CYP2E1—hematopoietic system—hematologic cancer	0.000548	0.0146	CbGeAlD
Sildenafil—ABCC4—lung—hematologic cancer	0.000521	0.0139	CbGeAlD
Sildenafil—ABCC5—lymph node—hematologic cancer	0.000514	0.0137	CbGeAlD
Sildenafil—CYP2C19—blood—hematologic cancer	0.000494	0.0132	CbGeAlD
Sildenafil—ABCC4—testis—hematologic cancer	0.000492	0.0131	CbGeAlD
Sildenafil—CYP3A4—hematopoietic system—hematologic cancer	0.000441	0.0117	CbGeAlD
Sildenafil—CYP2D6—hematopoietic system—hematologic cancer	0.000434	0.0116	CbGeAlD
Sildenafil—ABCC10—lymph node—hematologic cancer	0.00043	0.0114	CbGeAlD
Sildenafil—CYP1A1—blood—hematologic cancer	0.000398	0.0106	CbGeAlD
Sildenafil—CYP3A5—blood—hematologic cancer	0.000389	0.0104	CbGeAlD
Sildenafil—CYP2C9—blood—hematologic cancer	0.000383	0.0102	CbGeAlD
Sildenafil—CYP2E1—blood—hematologic cancer	0.000363	0.00967	CbGeAlD
Sildenafil—ABCC4—lymph node—hematologic cancer	0.000356	0.00948	CbGeAlD
Sildenafil—CYP1A1—lung—hematologic cancer	0.000349	0.00929	CbGeAlD
Sildenafil—CYP3A5—lung—hematologic cancer	0.000341	0.00909	CbGeAlD
Sildenafil—CYP2E1—lung—hematologic cancer	0.000318	0.00848	CbGeAlD
Sildenafil—CYP2E1—testis—hematologic cancer	0.0003	0.008	CbGeAlD
Sildenafil—CYP3A4—blood—hematologic cancer	0.000292	0.00778	CbGeAlD
Sildenafil—CYP2D6—blood—hematologic cancer	0.000288	0.00765	CbGeAlD
Sildenafil—CYP1A1—lymph node—hematologic cancer	0.000239	0.00636	CbGeAlD
Sildenafil—CYP2D6—testis—hematologic cancer	0.000238	0.00633	CbGeAlD
Sildenafil—Dermatitis—Cisplatin—hematologic cancer	1.33e-05	5.53e-05	CcSEcCtD
Sildenafil—Erythema—Epirubicin—hematologic cancer	1.33e-05	5.53e-05	CcSEcCtD
Sildenafil—Malnutrition—Epirubicin—hematologic cancer	1.33e-05	5.53e-05	CcSEcCtD
Sildenafil—Diarrhoea—Etoposide—hematologic cancer	1.32e-05	5.51e-05	CcSEcCtD
Sildenafil—Anorexia—Prednisone—hematologic cancer	1.32e-05	5.5e-05	CcSEcCtD
Sildenafil—Eye disorder—Doxorubicin—hematologic cancer	1.32e-05	5.49e-05	CcSEcCtD
Sildenafil—Ill-defined disorder—Methotrexate—hematologic cancer	1.32e-05	5.48e-05	CcSEcCtD
Sildenafil—Tinnitus—Doxorubicin—hematologic cancer	1.32e-05	5.48e-05	CcSEcCtD
Sildenafil—Anaemia—Methotrexate—hematologic cancer	1.31e-05	5.46e-05	CcSEcCtD
Sildenafil—Feeling abnormal—Betamethasone—hematologic cancer	1.31e-05	5.46e-05	CcSEcCtD
Sildenafil—Feeling abnormal—Dexamethasone—hematologic cancer	1.31e-05	5.46e-05	CcSEcCtD
Sildenafil—Flushing—Doxorubicin—hematologic cancer	1.31e-05	5.45e-05	CcSEcCtD
Sildenafil—Cardiac disorder—Doxorubicin—hematologic cancer	1.31e-05	5.45e-05	CcSEcCtD
Sildenafil—Flatulence—Epirubicin—hematologic cancer	1.31e-05	5.45e-05	CcSEcCtD
Sildenafil—Tension—Epirubicin—hematologic cancer	1.3e-05	5.42e-05	CcSEcCtD
Sildenafil—Gastrointestinal pain—Betamethasone—hematologic cancer	1.3e-05	5.42e-05	CcSEcCtD
Sildenafil—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.3e-05	5.42e-05	CcSEcCtD
Sildenafil—Hypersensitivity—Triamcinolone—hematologic cancer	1.29e-05	5.38e-05	CcSEcCtD
Sildenafil—Nervousness—Epirubicin—hematologic cancer	1.29e-05	5.37e-05	CcSEcCtD
Sildenafil—Back pain—Epirubicin—hematologic cancer	1.29e-05	5.35e-05	CcSEcCtD
Sildenafil—Angiopathy—Doxorubicin—hematologic cancer	1.28e-05	5.33e-05	CcSEcCtD
Sildenafil—Malaise—Methotrexate—hematologic cancer	1.28e-05	5.33e-05	CcSEcCtD
Sildenafil—Dizziness—Etoposide—hematologic cancer	1.28e-05	5.32e-05	CcSEcCtD
Sildenafil—Immune system disorder—Doxorubicin—hematologic cancer	1.28e-05	5.31e-05	CcSEcCtD
Sildenafil—Vertigo—Methotrexate—hematologic cancer	1.28e-05	5.31e-05	CcSEcCtD
Sildenafil—Mediastinal disorder—Doxorubicin—hematologic cancer	1.27e-05	5.29e-05	CcSEcCtD
Sildenafil—Leukopenia—Methotrexate—hematologic cancer	1.27e-05	5.29e-05	CcSEcCtD
Sildenafil—Chills—Doxorubicin—hematologic cancer	1.27e-05	5.27e-05	CcSEcCtD
Sildenafil—Urticaria—Betamethasone—hematologic cancer	1.27e-05	5.26e-05	CcSEcCtD
Sildenafil—Urticaria—Dexamethasone—hematologic cancer	1.27e-05	5.26e-05	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.26e-05	5.25e-05	CcSEcCtD
Sildenafil—Dizziness—Prednisolone—hematologic cancer	1.26e-05	5.25e-05	CcSEcCtD
Sildenafil—Arrhythmia—Doxorubicin—hematologic cancer	1.26e-05	5.25e-05	CcSEcCtD
Sildenafil—Asthenia—Triamcinolone—hematologic cancer	1.26e-05	5.24e-05	CcSEcCtD
Sildenafil—Abdominal pain—Dexamethasone—hematologic cancer	1.26e-05	5.24e-05	CcSEcCtD
Sildenafil—Body temperature increased—Dexamethasone—hematologic cancer	1.26e-05	5.24e-05	CcSEcCtD
Sildenafil—Body temperature increased—Betamethasone—hematologic cancer	1.26e-05	5.24e-05	CcSEcCtD
Sildenafil—Abdominal pain—Betamethasone—hematologic cancer	1.26e-05	5.24e-05	CcSEcCtD
Sildenafil—Nausea—Cisplatin—hematologic cancer	1.25e-05	5.22e-05	CcSEcCtD
Sildenafil—Insomnia—Prednisone—hematologic cancer	1.25e-05	5.22e-05	CcSEcCtD
Sildenafil—Vision blurred—Epirubicin—hematologic cancer	1.25e-05	5.21e-05	CcSEcCtD
Sildenafil—Alopecia—Doxorubicin—hematologic cancer	1.25e-05	5.19e-05	CcSEcCtD
Sildenafil—Paraesthesia—Prednisone—hematologic cancer	1.25e-05	5.18e-05	CcSEcCtD
Sildenafil—Pruritus—Triamcinolone—hematologic cancer	1.24e-05	5.16e-05	CcSEcCtD
Sildenafil—Cough—Methotrexate—hematologic cancer	1.24e-05	5.15e-05	CcSEcCtD
Sildenafil—Mental disorder—Doxorubicin—hematologic cancer	1.24e-05	5.15e-05	CcSEcCtD
Sildenafil—Ill-defined disorder—Epirubicin—hematologic cancer	1.23e-05	5.13e-05	CcSEcCtD
Sildenafil—Convulsion—Methotrexate—hematologic cancer	1.23e-05	5.12e-05	CcSEcCtD
Sildenafil—Vomiting—Etoposide—hematologic cancer	1.23e-05	5.12e-05	CcSEcCtD
Sildenafil—Erythema—Doxorubicin—hematologic cancer	1.23e-05	5.11e-05	CcSEcCtD
Sildenafil—Malnutrition—Doxorubicin—hematologic cancer	1.23e-05	5.11e-05	CcSEcCtD
Sildenafil—Anaemia—Epirubicin—hematologic cancer	1.23e-05	5.11e-05	CcSEcCtD
Sildenafil—Agitation—Epirubicin—hematologic cancer	1.22e-05	5.08e-05	CcSEcCtD
Sildenafil—Dyspepsia—Prednisone—hematologic cancer	1.22e-05	5.08e-05	CcSEcCtD
Sildenafil—Rash—Etoposide—hematologic cancer	1.22e-05	5.07e-05	CcSEcCtD
Sildenafil—Dermatitis—Etoposide—hematologic cancer	1.22e-05	5.07e-05	CcSEcCtD
Sildenafil—Headache—Etoposide—hematologic cancer	1.21e-05	5.04e-05	CcSEcCtD
Sildenafil—Flatulence—Doxorubicin—hematologic cancer	1.21e-05	5.04e-05	CcSEcCtD
Sildenafil—Arthralgia—Methotrexate—hematologic cancer	1.21e-05	5.03e-05	CcSEcCtD
Sildenafil—Chest pain—Methotrexate—hematologic cancer	1.21e-05	5.03e-05	CcSEcCtD
Sildenafil—Myalgia—Methotrexate—hematologic cancer	1.21e-05	5.03e-05	CcSEcCtD
Sildenafil—Tension—Doxorubicin—hematologic cancer	1.21e-05	5.02e-05	CcSEcCtD
Sildenafil—Decreased appetite—Prednisone—hematologic cancer	1.21e-05	5.01e-05	CcSEcCtD
Sildenafil—Rash—Prednisolone—hematologic cancer	1.2e-05	5e-05	CcSEcCtD
Sildenafil—Dermatitis—Prednisolone—hematologic cancer	1.2e-05	5e-05	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.2e-05	4.99e-05	CcSEcCtD
Sildenafil—Malaise—Epirubicin—hematologic cancer	1.2e-05	4.98e-05	CcSEcCtD
Sildenafil—Fatigue—Prednisone—hematologic cancer	1.2e-05	4.97e-05	CcSEcCtD
Sildenafil—Headache—Prednisolone—hematologic cancer	1.2e-05	4.97e-05	CcSEcCtD
Sildenafil—Discomfort—Methotrexate—hematologic cancer	1.19e-05	4.97e-05	CcSEcCtD
Sildenafil—Nervousness—Doxorubicin—hematologic cancer	1.19e-05	4.97e-05	CcSEcCtD
Sildenafil—Vertigo—Epirubicin—hematologic cancer	1.19e-05	4.97e-05	CcSEcCtD
Sildenafil—Syncope—Epirubicin—hematologic cancer	1.19e-05	4.96e-05	CcSEcCtD
Sildenafil—Leukopenia—Epirubicin—hematologic cancer	1.19e-05	4.95e-05	CcSEcCtD
Sildenafil—Back pain—Doxorubicin—hematologic cancer	1.19e-05	4.95e-05	CcSEcCtD
Sildenafil—Constipation—Prednisone—hematologic cancer	1.19e-05	4.93e-05	CcSEcCtD
Sildenafil—Palpitations—Epirubicin—hematologic cancer	1.17e-05	4.88e-05	CcSEcCtD
Sildenafil—Loss of consciousness—Epirubicin—hematologic cancer	1.17e-05	4.86e-05	CcSEcCtD
Sildenafil—Dizziness—Triamcinolone—hematologic cancer	1.16e-05	4.83e-05	CcSEcCtD
Sildenafil—Cough—Epirubicin—hematologic cancer	1.16e-05	4.82e-05	CcSEcCtD
Sildenafil—Vision blurred—Doxorubicin—hematologic cancer	1.16e-05	4.82e-05	CcSEcCtD
Sildenafil—Convulsion—Epirubicin—hematologic cancer	1.15e-05	4.79e-05	CcSEcCtD
Sildenafil—Infection—Methotrexate—hematologic cancer	1.15e-05	4.79e-05	CcSEcCtD
Sildenafil—Nausea—Etoposide—hematologic cancer	1.15e-05	4.78e-05	CcSEcCtD
Sildenafil—Hypertension—Epirubicin—hematologic cancer	1.15e-05	4.77e-05	CcSEcCtD
Sildenafil—Feeling abnormal—Prednisone—hematologic cancer	1.14e-05	4.75e-05	CcSEcCtD
Sildenafil—Asthenia—Dexamethasone—hematologic cancer	1.14e-05	4.75e-05	CcSEcCtD
Sildenafil—Asthenia—Betamethasone—hematologic cancer	1.14e-05	4.75e-05	CcSEcCtD
Sildenafil—Ill-defined disorder—Doxorubicin—hematologic cancer	1.14e-05	4.75e-05	CcSEcCtD
Sildenafil—Nervous system disorder—Methotrexate—hematologic cancer	1.14e-05	4.73e-05	CcSEcCtD
Sildenafil—Anaemia—Doxorubicin—hematologic cancer	1.14e-05	4.73e-05	CcSEcCtD
Sildenafil—Gastrointestinal pain—Prednisone—hematologic cancer	1.13e-05	4.72e-05	CcSEcCtD
Sildenafil—Nausea—Prednisolone—hematologic cancer	1.13e-05	4.71e-05	CcSEcCtD
Sildenafil—Arthralgia—Epirubicin—hematologic cancer	1.13e-05	4.71e-05	CcSEcCtD
Sildenafil—Chest pain—Epirubicin—hematologic cancer	1.13e-05	4.71e-05	CcSEcCtD
Sildenafil—Myalgia—Epirubicin—hematologic cancer	1.13e-05	4.71e-05	CcSEcCtD
Sildenafil—Agitation—Doxorubicin—hematologic cancer	1.13e-05	4.7e-05	CcSEcCtD
Sildenafil—Anxiety—Epirubicin—hematologic cancer	1.13e-05	4.69e-05	CcSEcCtD
Sildenafil—Pruritus—Betamethasone—hematologic cancer	1.13e-05	4.69e-05	CcSEcCtD
Sildenafil—Pruritus—Dexamethasone—hematologic cancer	1.13e-05	4.69e-05	CcSEcCtD
Sildenafil—Skin disorder—Methotrexate—hematologic cancer	1.13e-05	4.68e-05	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.12e-05	4.67e-05	CcSEcCtD
Sildenafil—Hyperhidrosis—Methotrexate—hematologic cancer	1.12e-05	4.66e-05	CcSEcCtD
Sildenafil—Discomfort—Epirubicin—hematologic cancer	1.12e-05	4.65e-05	CcSEcCtD
Sildenafil—Vomiting—Triamcinolone—hematologic cancer	1.12e-05	4.64e-05	CcSEcCtD
Sildenafil—Malaise—Doxorubicin—hematologic cancer	1.11e-05	4.61e-05	CcSEcCtD
Sildenafil—Rash—Triamcinolone—hematologic cancer	1.11e-05	4.6e-05	CcSEcCtD
Sildenafil—Dry mouth—Epirubicin—hematologic cancer	1.11e-05	4.6e-05	CcSEcCtD
Sildenafil—Dermatitis—Triamcinolone—hematologic cancer	1.11e-05	4.6e-05	CcSEcCtD
Sildenafil—Vertigo—Doxorubicin—hematologic cancer	1.1e-05	4.59e-05	CcSEcCtD
Sildenafil—Anorexia—Methotrexate—hematologic cancer	1.1e-05	4.59e-05	CcSEcCtD
Sildenafil—Syncope—Doxorubicin—hematologic cancer	1.1e-05	4.59e-05	CcSEcCtD
Sildenafil—Urticaria—Prednisone—hematologic cancer	1.1e-05	4.58e-05	CcSEcCtD
Sildenafil—Leukopenia—Doxorubicin—hematologic cancer	1.1e-05	4.58e-05	CcSEcCtD
Sildenafil—Headache—Triamcinolone—hematologic cancer	1.1e-05	4.57e-05	CcSEcCtD
Sildenafil—Abdominal pain—Prednisone—hematologic cancer	1.1e-05	4.56e-05	CcSEcCtD
Sildenafil—Body temperature increased—Prednisone—hematologic cancer	1.1e-05	4.56e-05	CcSEcCtD
Sildenafil—Diarrhoea—Betamethasone—hematologic cancer	1.09e-05	4.53e-05	CcSEcCtD
Sildenafil—Diarrhoea—Dexamethasone—hematologic cancer	1.09e-05	4.53e-05	CcSEcCtD
Sildenafil—Palpitations—Doxorubicin—hematologic cancer	1.09e-05	4.52e-05	CcSEcCtD
Sildenafil—Oedema—Epirubicin—hematologic cancer	1.08e-05	4.51e-05	CcSEcCtD
Sildenafil—Hypotension—Methotrexate—hematologic cancer	1.08e-05	4.5e-05	CcSEcCtD
Sildenafil—Loss of consciousness—Doxorubicin—hematologic cancer	1.08e-05	4.5e-05	CcSEcCtD
Sildenafil—Infection—Epirubicin—hematologic cancer	1.08e-05	4.48e-05	CcSEcCtD
Sildenafil—Cough—Doxorubicin—hematologic cancer	1.07e-05	4.46e-05	CcSEcCtD
Sildenafil—Shock—Epirubicin—hematologic cancer	1.07e-05	4.44e-05	CcSEcCtD
Sildenafil—Convulsion—Doxorubicin—hematologic cancer	1.07e-05	4.43e-05	CcSEcCtD
Sildenafil—Nervous system disorder—Epirubicin—hematologic cancer	1.06e-05	4.42e-05	CcSEcCtD
Sildenafil—Hypertension—Doxorubicin—hematologic cancer	1.06e-05	4.42e-05	CcSEcCtD
Sildenafil—Tachycardia—Epirubicin—hematologic cancer	1.06e-05	4.4e-05	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.06e-05	4.39e-05	CcSEcCtD
Sildenafil—Skin disorder—Epirubicin—hematologic cancer	1.05e-05	4.38e-05	CcSEcCtD
Sildenafil—Dizziness—Dexamethasone—hematologic cancer	1.05e-05	4.38e-05	CcSEcCtD
Sildenafil—Dizziness—Betamethasone—hematologic cancer	1.05e-05	4.38e-05	CcSEcCtD
Sildenafil—Hyperhidrosis—Epirubicin—hematologic cancer	1.05e-05	4.36e-05	CcSEcCtD
Sildenafil—Insomnia—Methotrexate—hematologic cancer	1.05e-05	4.36e-05	CcSEcCtD
Sildenafil—Chest pain—Doxorubicin—hematologic cancer	1.05e-05	4.35e-05	CcSEcCtD
Sildenafil—Myalgia—Doxorubicin—hematologic cancer	1.05e-05	4.35e-05	CcSEcCtD
Sildenafil—Arthralgia—Doxorubicin—hematologic cancer	1.05e-05	4.35e-05	CcSEcCtD
Sildenafil—Anxiety—Doxorubicin—hematologic cancer	1.04e-05	4.34e-05	CcSEcCtD
Sildenafil—Nausea—Triamcinolone—hematologic cancer	1.04e-05	4.34e-05	CcSEcCtD
Sildenafil—Paraesthesia—Methotrexate—hematologic cancer	1.04e-05	4.33e-05	CcSEcCtD
Sildenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.04e-05	4.32e-05	CcSEcCtD
Sildenafil—Discomfort—Doxorubicin—hematologic cancer	1.03e-05	4.3e-05	CcSEcCtD
Sildenafil—Anorexia—Epirubicin—hematologic cancer	1.03e-05	4.3e-05	CcSEcCtD
Sildenafil—Dyspnoea—Methotrexate—hematologic cancer	1.03e-05	4.3e-05	CcSEcCtD
Sildenafil—Somnolence—Methotrexate—hematologic cancer	1.03e-05	4.29e-05	CcSEcCtD
Sildenafil—Dry mouth—Doxorubicin—hematologic cancer	1.02e-05	4.26e-05	CcSEcCtD
Sildenafil—Hypersensitivity—Prednisone—hematologic cancer	1.02e-05	4.25e-05	CcSEcCtD
Sildenafil—Dyspepsia—Methotrexate—hematologic cancer	1.02e-05	4.24e-05	CcSEcCtD
Sildenafil—Hypotension—Epirubicin—hematologic cancer	1.01e-05	4.22e-05	CcSEcCtD
Sildenafil—Vomiting—Betamethasone—hematologic cancer	1.01e-05	4.21e-05	CcSEcCtD
Sildenafil—Vomiting—Dexamethasone—hematologic cancer	1.01e-05	4.21e-05	CcSEcCtD
Sildenafil—Decreased appetite—Methotrexate—hematologic cancer	1.01e-05	4.19e-05	CcSEcCtD
Sildenafil—Rash—Dexamethasone—hematologic cancer	1e-05	4.18e-05	CcSEcCtD
Sildenafil—Rash—Betamethasone—hematologic cancer	1e-05	4.18e-05	CcSEcCtD
Sildenafil—Oedema—Doxorubicin—hematologic cancer	1e-05	4.17e-05	CcSEcCtD
Sildenafil—Dermatitis—Dexamethasone—hematologic cancer	1e-05	4.17e-05	CcSEcCtD
Sildenafil—Dermatitis—Betamethasone—hematologic cancer	1e-05	4.17e-05	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Methotrexate—hematologic cancer	1e-05	4.16e-05	CcSEcCtD
Sildenafil—Fatigue—Methotrexate—hematologic cancer	9.99e-06	4.16e-05	CcSEcCtD
Sildenafil—Headache—Dexamethasone—hematologic cancer	9.98e-06	4.15e-05	CcSEcCtD
Sildenafil—Headache—Betamethasone—hematologic cancer	9.98e-06	4.15e-05	CcSEcCtD
Sildenafil—Infection—Doxorubicin—hematologic cancer	9.97e-06	4.15e-05	CcSEcCtD
Sildenafil—Asthenia—Prednisone—hematologic cancer	9.95e-06	4.14e-05	CcSEcCtD
Sildenafil—Pain—Methotrexate—hematologic cancer	9.91e-06	4.12e-05	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.88e-06	4.11e-05	CcSEcCtD
Sildenafil—Shock—Doxorubicin—hematologic cancer	9.87e-06	4.11e-05	CcSEcCtD
Sildenafil—Nervous system disorder—Doxorubicin—hematologic cancer	9.84e-06	4.09e-05	CcSEcCtD
Sildenafil—Pruritus—Prednisone—hematologic cancer	9.81e-06	4.08e-05	CcSEcCtD
Sildenafil—Insomnia—Epirubicin—hematologic cancer	9.81e-06	4.08e-05	CcSEcCtD
Sildenafil—Tachycardia—Doxorubicin—hematologic cancer	9.79e-06	4.07e-05	CcSEcCtD
Sildenafil—Skin disorder—Doxorubicin—hematologic cancer	9.75e-06	4.05e-05	CcSEcCtD
Sildenafil—Paraesthesia—Epirubicin—hematologic cancer	9.74e-06	4.05e-05	CcSEcCtD
Sildenafil—Hyperhidrosis—Doxorubicin—hematologic cancer	9.7e-06	4.04e-05	CcSEcCtD
Sildenafil—Dyspnoea—Epirubicin—hematologic cancer	9.67e-06	4.02e-05	CcSEcCtD
Sildenafil—Somnolence—Epirubicin—hematologic cancer	9.64e-06	4.01e-05	CcSEcCtD
Sildenafil—Anorexia—Doxorubicin—hematologic cancer	9.57e-06	3.98e-05	CcSEcCtD
Sildenafil—Feeling abnormal—Methotrexate—hematologic cancer	9.55e-06	3.97e-05	CcSEcCtD
Sildenafil—Dyspepsia—Epirubicin—hematologic cancer	9.55e-06	3.97e-05	CcSEcCtD
Sildenafil—Diarrhoea—Prednisone—hematologic cancer	9.49e-06	3.95e-05	CcSEcCtD
Sildenafil—Gastrointestinal pain—Methotrexate—hematologic cancer	9.48e-06	3.94e-05	CcSEcCtD
Sildenafil—Nausea—Dexamethasone—hematologic cancer	9.46e-06	3.93e-05	CcSEcCtD
Sildenafil—Nausea—Betamethasone—hematologic cancer	9.46e-06	3.93e-05	CcSEcCtD
Sildenafil—Decreased appetite—Epirubicin—hematologic cancer	9.43e-06	3.92e-05	CcSEcCtD
Sildenafil—Hypotension—Doxorubicin—hematologic cancer	9.38e-06	3.9e-05	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Epirubicin—hematologic cancer	9.36e-06	3.89e-05	CcSEcCtD
Sildenafil—Fatigue—Epirubicin—hematologic cancer	9.35e-06	3.89e-05	CcSEcCtD
Sildenafil—Pain—Epirubicin—hematologic cancer	9.28e-06	3.86e-05	CcSEcCtD
Sildenafil—Constipation—Epirubicin—hematologic cancer	9.28e-06	3.86e-05	CcSEcCtD
Sildenafil—Urticaria—Methotrexate—hematologic cancer	9.21e-06	3.83e-05	CcSEcCtD
Sildenafil—Dizziness—Prednisone—hematologic cancer	9.17e-06	3.81e-05	CcSEcCtD
Sildenafil—Body temperature increased—Methotrexate—hematologic cancer	9.16e-06	3.81e-05	CcSEcCtD
Sildenafil—Abdominal pain—Methotrexate—hematologic cancer	9.16e-06	3.81e-05	CcSEcCtD
Sildenafil—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	9.14e-06	3.8e-05	CcSEcCtD
Sildenafil—Insomnia—Doxorubicin—hematologic cancer	9.08e-06	3.78e-05	CcSEcCtD
Sildenafil—Paraesthesia—Doxorubicin—hematologic cancer	9.01e-06	3.75e-05	CcSEcCtD
Sildenafil—Dyspnoea—Doxorubicin—hematologic cancer	8.95e-06	3.72e-05	CcSEcCtD
Sildenafil—Feeling abnormal—Epirubicin—hematologic cancer	8.94e-06	3.72e-05	CcSEcCtD
Sildenafil—Somnolence—Doxorubicin—hematologic cancer	8.92e-06	3.71e-05	CcSEcCtD
Sildenafil—Gastrointestinal pain—Epirubicin—hematologic cancer	8.87e-06	3.69e-05	CcSEcCtD
Sildenafil—Dyspepsia—Doxorubicin—hematologic cancer	8.83e-06	3.67e-05	CcSEcCtD
Sildenafil—Vomiting—Prednisone—hematologic cancer	8.82e-06	3.67e-05	CcSEcCtD
Sildenafil—Rash—Prednisone—hematologic cancer	8.74e-06	3.64e-05	CcSEcCtD
Sildenafil—Dermatitis—Prednisone—hematologic cancer	8.74e-06	3.63e-05	CcSEcCtD
Sildenafil—Decreased appetite—Doxorubicin—hematologic cancer	8.72e-06	3.63e-05	CcSEcCtD
Sildenafil—Headache—Prednisone—hematologic cancer	8.69e-06	3.61e-05	CcSEcCtD
Sildenafil—Gastrointestinal disorder—Doxorubicin—hematologic cancer	8.66e-06	3.6e-05	CcSEcCtD
Sildenafil—Fatigue—Doxorubicin—hematologic cancer	8.65e-06	3.6e-05	CcSEcCtD
Sildenafil—Urticaria—Epirubicin—hematologic cancer	8.62e-06	3.58e-05	CcSEcCtD
Sildenafil—Pain—Doxorubicin—hematologic cancer	8.58e-06	3.57e-05	CcSEcCtD
Sildenafil—Constipation—Doxorubicin—hematologic cancer	8.58e-06	3.57e-05	CcSEcCtD
Sildenafil—Body temperature increased—Epirubicin—hematologic cancer	8.57e-06	3.57e-05	CcSEcCtD
Sildenafil—Abdominal pain—Epirubicin—hematologic cancer	8.57e-06	3.57e-05	CcSEcCtD
Sildenafil—Hypersensitivity—Methotrexate—hematologic cancer	8.54e-06	3.55e-05	CcSEcCtD
Sildenafil—Asthenia—Methotrexate—hematologic cancer	8.32e-06	3.46e-05	CcSEcCtD
Sildenafil—Feeling abnormal—Doxorubicin—hematologic cancer	8.27e-06	3.44e-05	CcSEcCtD
Sildenafil—Nausea—Prednisone—hematologic cancer	8.24e-06	3.43e-05	CcSEcCtD
Sildenafil—Gastrointestinal pain—Doxorubicin—hematologic cancer	8.21e-06	3.41e-05	CcSEcCtD
Sildenafil—Pruritus—Methotrexate—hematologic cancer	8.2e-06	3.41e-05	CcSEcCtD
Sildenafil—Hypersensitivity—Epirubicin—hematologic cancer	7.99e-06	3.32e-05	CcSEcCtD
Sildenafil—Urticaria—Doxorubicin—hematologic cancer	7.97e-06	3.32e-05	CcSEcCtD
Sildenafil—Body temperature increased—Doxorubicin—hematologic cancer	7.93e-06	3.3e-05	CcSEcCtD
Sildenafil—Abdominal pain—Doxorubicin—hematologic cancer	7.93e-06	3.3e-05	CcSEcCtD
Sildenafil—Diarrhoea—Methotrexate—hematologic cancer	7.93e-06	3.3e-05	CcSEcCtD
Sildenafil—Asthenia—Epirubicin—hematologic cancer	7.78e-06	3.24e-05	CcSEcCtD
Sildenafil—Pruritus—Epirubicin—hematologic cancer	7.67e-06	3.19e-05	CcSEcCtD
Sildenafil—Dizziness—Methotrexate—hematologic cancer	7.66e-06	3.19e-05	CcSEcCtD
Sildenafil—Diarrhoea—Epirubicin—hematologic cancer	7.42e-06	3.09e-05	CcSEcCtD
Sildenafil—Hypersensitivity—Doxorubicin—hematologic cancer	7.39e-06	3.08e-05	CcSEcCtD
Sildenafil—Vomiting—Methotrexate—hematologic cancer	7.37e-06	3.06e-05	CcSEcCtD
Sildenafil—Rash—Methotrexate—hematologic cancer	7.31e-06	3.04e-05	CcSEcCtD
Sildenafil—Dermatitis—Methotrexate—hematologic cancer	7.3e-06	3.04e-05	CcSEcCtD
Sildenafil—Headache—Methotrexate—hematologic cancer	7.26e-06	3.02e-05	CcSEcCtD
Sildenafil—Asthenia—Doxorubicin—hematologic cancer	7.2e-06	2.99e-05	CcSEcCtD
Sildenafil—Dizziness—Epirubicin—hematologic cancer	7.17e-06	2.98e-05	CcSEcCtD
Sildenafil—Pruritus—Doxorubicin—hematologic cancer	7.1e-06	2.95e-05	CcSEcCtD
Sildenafil—Vomiting—Epirubicin—hematologic cancer	6.9e-06	2.87e-05	CcSEcCtD
Sildenafil—Nausea—Methotrexate—hematologic cancer	6.88e-06	2.86e-05	CcSEcCtD
Sildenafil—Diarrhoea—Doxorubicin—hematologic cancer	6.87e-06	2.86e-05	CcSEcCtD
Sildenafil—Rash—Epirubicin—hematologic cancer	6.84e-06	2.84e-05	CcSEcCtD
Sildenafil—Dermatitis—Epirubicin—hematologic cancer	6.83e-06	2.84e-05	CcSEcCtD
Sildenafil—Headache—Epirubicin—hematologic cancer	6.79e-06	2.83e-05	CcSEcCtD
Sildenafil—Dizziness—Doxorubicin—hematologic cancer	6.64e-06	2.76e-05	CcSEcCtD
Sildenafil—Nausea—Epirubicin—hematologic cancer	6.44e-06	2.68e-05	CcSEcCtD
Sildenafil—Vomiting—Doxorubicin—hematologic cancer	6.38e-06	2.65e-05	CcSEcCtD
Sildenafil—Rash—Doxorubicin—hematologic cancer	6.33e-06	2.63e-05	CcSEcCtD
Sildenafil—Dermatitis—Doxorubicin—hematologic cancer	6.32e-06	2.63e-05	CcSEcCtD
Sildenafil—Headache—Doxorubicin—hematologic cancer	6.29e-06	2.61e-05	CcSEcCtD
Sildenafil—Nausea—Doxorubicin—hematologic cancer	5.96e-06	2.48e-05	CcSEcCtD
Sildenafil—CYP2E1—Metabolism—CYCS—hematologic cancer	3.98e-06	5.51e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—CYCS—hematologic cancer	3.97e-06	5.5e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—CD44—hematologic cancer	3.97e-06	5.49e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—NQO1—hematologic cancer	3.97e-06	5.49e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NUP98—hematologic cancer	3.97e-06	5.49e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—HSP90AA1—hematologic cancer	3.96e-06	5.48e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—HSP90AA1—hematologic cancer	3.95e-06	5.47e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—MTHFR—hematologic cancer	3.94e-06	5.45e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GSTT1—hematologic cancer	3.91e-06	5.41e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.89e-06	5.38e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ADCY7—hematologic cancer	3.88e-06	5.38e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NCOA3—hematologic cancer	3.88e-06	5.38e-05	CbGpPWpGaD
Sildenafil—PDE6G—Signaling Pathways—AKT1—hematologic cancer	3.88e-06	5.37e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NUP214—hematologic cancer	3.86e-06	5.34e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ADCY7—hematologic cancer	3.85e-06	5.33e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NCOA3—hematologic cancer	3.85e-06	5.33e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.85e-06	5.32e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MAP2K1—hematologic cancer	3.84e-06	5.31e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—FHL2—hematologic cancer	3.83e-06	5.31e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NUP214—hematologic cancer	3.82e-06	5.29e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—SDC1—hematologic cancer	3.82e-06	5.29e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—PIK3CD—hematologic cancer	3.81e-06	5.28e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	3.78e-06	5.24e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ABCG2—hematologic cancer	3.78e-06	5.23e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—MTR—hematologic cancer	3.78e-06	5.23e-05	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	3.78e-06	5.23e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—AGRN—hematologic cancer	3.76e-06	5.2e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—CYCS—hematologic cancer	3.76e-06	5.2e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—MTR—hematologic cancer	3.75e-06	5.18e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ABCG2—hematologic cancer	3.75e-06	5.18e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—KRAS—hematologic cancer	3.73e-06	5.17e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—HSP90AA1—hematologic cancer	3.73e-06	5.16e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ENO2—hematologic cancer	3.71e-06	5.13e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ENO2—hematologic cancer	3.67e-06	5.08e-05	CbGpPWpGaD
Sildenafil—ABCC5—Disease—PIK3CA—hematologic cancer	3.66e-06	5.07e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—FGF2—hematologic cancer	3.65e-06	5.05e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.65e-06	5.05e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—PIK3R1—hematologic cancer	3.6e-06	4.98e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.6e-06	4.98e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GSTT1—hematologic cancer	3.59e-06	4.97e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—HMMR—hematologic cancer	3.56e-06	4.93e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—IDH2—hematologic cancer	3.56e-06	4.93e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GSTT1—hematologic cancer	3.56e-06	4.93e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—SDC1—hematologic cancer	3.51e-06	4.86e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GSTP1—hematologic cancer	3.51e-06	4.86e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	3.51e-06	4.86e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GSTP1—hematologic cancer	3.5e-06	4.85e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—JAK2—hematologic cancer	3.5e-06	4.84e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—SDC1—hematologic cancer	3.48e-06	4.82e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.45e-06	4.77e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—PIK3CA—hematologic cancer	3.43e-06	4.75e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MDM2—hematologic cancer	3.42e-06	4.73e-05	CbGpPWpGaD
Sildenafil—ABCC5—Disease—HRAS—hematologic cancer	3.39e-06	4.69e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.36e-06	4.65e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ARNTL—hematologic cancer	3.35e-06	4.64e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	3.33e-06	4.6e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MTOR—hematologic cancer	3.32e-06	4.6e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—PIK3CB—hematologic cancer	3.32e-06	4.6e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—ABCB1—hematologic cancer	3.32e-06	4.6e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—ABCB1—hematologic cancer	3.32e-06	4.59e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GSTP1—hematologic cancer	3.31e-06	4.58e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PIK3CG—hematologic cancer	3.31e-06	4.58e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	3.28e-06	4.54e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ACP5—hematologic cancer	3.26e-06	4.51e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CA9—hematologic cancer	3.26e-06	4.51e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—CD44—hematologic cancer	3.25e-06	4.49e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—NQO1—hematologic cancer	3.25e-06	4.49e-05	CbGpPWpGaD
Sildenafil—ABCC5—Disease—IL6—hematologic cancer	3.24e-06	4.49e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—GSTM1—hematologic cancer	3.23e-06	4.46e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—NCOR1—hematologic cancer	3.23e-06	4.46e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—GSTM1—hematologic cancer	3.22e-06	4.46e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—NCOR1—hematologic cancer	3.22e-06	4.46e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NCOR2—hematologic cancer	3.22e-06	4.45e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.2e-06	4.43e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.18e-06	4.4e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—HRAS—hematologic cancer	3.17e-06	4.39e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	3.14e-06	4.35e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—ABCB1—hematologic cancer	3.13e-06	4.34e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CDKN1B—hematologic cancer	3.12e-06	4.32e-05	CbGpPWpGaD
Sildenafil—ADORA2A—GPCR downstream signaling—AKT1—hematologic cancer	3.09e-06	4.27e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—CYCS—hematologic cancer	3.07e-06	4.25e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—CREBBP—hematologic cancer	3.07e-06	4.24e-05	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—PIK3CA—hematologic cancer	3.07e-06	4.24e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—IDH1—hematologic cancer	3.06e-06	4.24e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CASP3—hematologic cancer	3.06e-06	4.23e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—HSP90AA1—hematologic cancer	3.05e-06	4.23e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—IL2—hematologic cancer	3.05e-06	4.23e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—GSTM1—hematologic cancer	3.04e-06	4.21e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—NCOR1—hematologic cancer	3.04e-06	4.21e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—IL6—hematologic cancer	3.04e-06	4.2e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTO1—hematologic cancer	3.03e-06	4.19e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—TXN—hematologic cancer	3.03e-06	4.19e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ABCC3—hematologic cancer	3.03e-06	4.19e-05	CbGpPWpGaD
Sildenafil—ABCC5—Disease—AKT1—hematologic cancer	2.99e-06	4.14e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NQO1—hematologic cancer	2.99e-06	4.13e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—CD44—hematologic cancer	2.99e-06	4.13e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CCND1—hematologic cancer	2.98e-06	4.12e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—JUN—hematologic cancer	2.97e-06	4.11e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—SPHK1—hematologic cancer	2.97e-06	4.1e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NQO1—hematologic cancer	2.96e-06	4.1e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—CD44—hematologic cancer	2.96e-06	4.1e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PIK3CD—hematologic cancer	2.91e-06	4.02e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.9e-06	4.01e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—CDKN1A—hematologic cancer	2.88e-06	3.98e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—PTEN—hematologic cancer	2.87e-06	3.98e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—ALB—hematologic cancer	2.87e-06	3.97e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—MTHFR—hematologic cancer	2.85e-06	3.95e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—UGT1A1—hematologic cancer	2.85e-06	3.94e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—MTHFR—hematologic cancer	2.85e-06	3.94e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—CYCS—hematologic cancer	2.83e-06	3.91e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MAPK8—hematologic cancer	2.81e-06	3.89e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	2.81e-06	3.89e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling by GPCR—AKT1—hematologic cancer	2.8e-06	3.88e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—CYCS—hematologic cancer	2.8e-06	3.88e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	2.78e-06	3.85e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—SLC22A1—hematologic cancer	2.77e-06	3.84e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CRABP1—hematologic cancer	2.77e-06	3.84e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.75e-06	3.8e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PIK3R1—hematologic cancer	2.75e-06	3.8e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—EP300—hematologic cancer	2.74e-06	3.79e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GSTP1—hematologic cancer	2.71e-06	3.75e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ALOX5—hematologic cancer	2.7e-06	3.74e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—MTHFR—hematologic cancer	2.69e-06	3.72e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—SRC—hematologic cancer	2.66e-06	3.69e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.62e-06	3.63e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NUP98—hematologic cancer	2.62e-06	3.62e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—VEGFA—hematologic cancer	2.59e-06	3.59e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—STAT3—hematologic cancer	2.57e-06	3.56e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—ABCB1—hematologic cancer	2.56e-06	3.55e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—NRAS—hematologic cancer	2.56e-06	3.55e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ADCY7—hematologic cancer	2.54e-06	3.51e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NCOA3—hematologic cancer	2.54e-06	3.51e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PIK3CB—hematologic cancer	2.53e-06	3.51e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NUP214—hematologic cancer	2.52e-06	3.49e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.51e-06	3.47e-05	CbGpPWpGaD
Sildenafil—ABCC5—Metabolism—AKT1—hematologic cancer	2.5e-06	3.47e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.49e-06	3.45e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.49e-06	3.44e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.49e-06	3.44e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—MTR—hematologic cancer	2.47e-06	3.42e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.47e-06	3.42e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GSTP1—hematologic cancer	2.47e-06	3.42e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MAPK3—hematologic cancer	2.45e-06	3.4e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ENO2—hematologic cancer	2.42e-06	3.35e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PIK3CG—hematologic cancer	2.4e-06	3.32e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PIK3CG—hematologic cancer	2.39e-06	3.31e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.39e-06	3.31e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—MYC—hematologic cancer	2.39e-06	3.3e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—TGFB1—hematologic cancer	2.38e-06	3.3e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.37e-06	3.28e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.36e-06	3.26e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.35e-06	3.25e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ABCB1—hematologic cancer	2.34e-06	3.24e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—SDC1—hematologic cancer	2.3e-06	3.18e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.29e-06	3.17e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.29e-06	3.17e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—NCOR1—hematologic cancer	2.27e-06	3.14e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—GSTM1—hematologic cancer	2.27e-06	3.14e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PIK3CG—hematologic cancer	2.26e-06	3.13e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—CREBBP—hematologic cancer	2.22e-06	3.07e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—CREBBP—hematologic cancer	2.22e-06	3.07e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—KRAS—hematologic cancer	2.21e-06	3.05e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—MTHFR—hematologic cancer	2.2e-06	3.04e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PTEN—hematologic cancer	2.19e-06	3.03e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PIK3CD—hematologic cancer	2.11e-06	2.91e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PIK3CD—hematologic cancer	2.1e-06	2.91e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—CREBBP—hematologic cancer	2.09e-06	2.9e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—EP300—hematologic cancer	2.09e-06	2.89e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—ALB—hematologic cancer	2.08e-06	2.88e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—ALB—hematologic cancer	2.07e-06	2.87e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—PIK3CA—hematologic cancer	2.03e-06	2.8e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.02e-06	2.8e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—MTHFR—hematologic cancer	2.01e-06	2.78e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PIK3R1—hematologic cancer	1.99e-06	2.75e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PIK3CD—hematologic cancer	1.99e-06	2.75e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.98e-06	2.75e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—TP53—hematologic cancer	1.96e-06	2.71e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—ALB—hematologic cancer	1.96e-06	2.71e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CD44—hematologic cancer	1.95e-06	2.7e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NQO1—hematologic cancer	1.95e-06	2.7e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.94e-06	2.68e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—HRAS—hematologic cancer	1.88e-06	2.59e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PIK3R1—hematologic cancer	1.87e-06	2.59e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.85e-06	2.56e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CYCS—hematologic cancer	1.85e-06	2.56e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.84e-06	2.54e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PIK3CB—hematologic cancer	1.84e-06	2.54e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.83e-06	2.53e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—IL6—hematologic cancer	1.79e-06	2.48e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.77e-06	2.45e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PIK3CB—hematologic cancer	1.73e-06	2.39e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.71e-06	2.37e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.7e-06	2.35e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PIK3CG—hematologic cancer	1.69e-06	2.33e-05	CbGpPWpGaD
Sildenafil—ADORA2A—Signaling Pathways—AKT1—hematologic cancer	1.66e-06	2.29e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.63e-06	2.25e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.62e-06	2.25e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—ALB—hematologic cancer	1.6e-06	2.22e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PTEN—hematologic cancer	1.59e-06	2.19e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PTEN—hematologic cancer	1.58e-06	2.19e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.58e-06	2.18e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—CREBBP—hematologic cancer	1.56e-06	2.16e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—PIK3CA—hematologic cancer	1.54e-06	2.14e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.54e-06	2.13e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.53e-06	2.12e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—EP300—hematologic cancer	1.51e-06	2.09e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—EP300—hematologic cancer	1.51e-06	2.09e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.5e-06	2.07e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.5e-06	2.07e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PTEN—hematologic cancer	1.5e-06	2.07e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.49e-06	2.07e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PIK3CD—hematologic cancer	1.48e-06	2.05e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—ALB—hematologic cancer	1.48e-06	2.04e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—ALB—hematologic cancer	1.46e-06	2.02e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—EP300—hematologic cancer	1.43e-06	1.97e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.42e-06	1.96e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.41e-06	1.95e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PIK3R1—hematologic cancer	1.4e-06	1.94e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.32e-06	1.83e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.3e-06	1.8e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PIK3CB—hematologic cancer	1.29e-06	1.79e-05	CbGpPWpGaD
Sildenafil—CYP3A7—Metabolism—AKT1—hematologic cancer	1.26e-06	1.75e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PTEN—hematologic cancer	1.22e-06	1.69e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—EP300—hematologic cancer	1.17e-06	1.61e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PTEN—hematologic cancer	1.13e-06	1.56e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—PIK3CA—hematologic cancer	1.12e-06	1.55e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.12e-06	1.55e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PTEN—hematologic cancer	1.12e-06	1.54e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.11e-06	1.54e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—EP300—hematologic cancer	1.07e-06	1.49e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—EP300—hematologic cancer	1.06e-06	1.47e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—PIK3CA—hematologic cancer	1.05e-06	1.46e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.03e-06	1.43e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PIK3CD—hematologic cancer	9.77e-07	1.35e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—ALB—hematologic cancer	9.65e-07	1.33e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PIK3R1—hematologic cancer	9.23e-07	1.28e-05	CbGpPWpGaD
Sildenafil—CYP2E1—Metabolism—AKT1—hematologic cancer	9.14e-07	1.26e-05	CbGpPWpGaD
Sildenafil—CYP3A5—Metabolism—AKT1—hematologic cancer	9.12e-07	1.26e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—PIK3CA—hematologic cancer	8.63e-07	1.19e-05	CbGpPWpGaD
Sildenafil—CYP1A1—Metabolism—AKT1—hematologic cancer	8.62e-07	1.19e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PIK3CB—hematologic cancer	8.52e-07	1.18e-05	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—PIK3CA—hematologic cancer	7.94e-07	1.1e-05	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—PIK3CA—hematologic cancer	7.87e-07	1.09e-05	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PTEN—hematologic cancer	7.36e-07	1.02e-05	CbGpPWpGaD
Sildenafil—CYP2C19—Metabolism—AKT1—hematologic cancer	7.05e-07	9.76e-06	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—EP300—hematologic cancer	7.02e-07	9.71e-06	CbGpPWpGaD
Sildenafil—CYP2D6—Metabolism—AKT1—hematologic cancer	6.49e-07	8.98e-06	CbGpPWpGaD
Sildenafil—CYP2C9—Metabolism—AKT1—hematologic cancer	6.43e-07	8.9e-06	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—PIK3CA—hematologic cancer	5.19e-07	7.18e-06	CbGpPWpGaD
Sildenafil—CYP3A4—Metabolism—AKT1—hematologic cancer	4.24e-07	5.87e-06	CbGpPWpGaD
